The "Global Cancer Immunotherapy Market Analysis & Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
Immunotherapy is forecast to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. Multiple treatment lines, combination therapy and the opportunity for repeat treatment are likely to accelerate fast growth. Cancer immunotherapy also expands into multiple indications and our analysis indicates that key immunotherapies including anti-PD-1 drugs, dendritic cell vaccines, T-cell therapies, and cancer vaccines are all driving the market. The rising incidence and prevalence of numerous cancers globally is a significant accelerator of growth. This is due to more sensitive early detection techniques, higher patient awareness, and a growing aging population. Furthermore, the FDA's pro-science attitude will accelerate development and regulatory approval for these drugs. To that end, the cancer immunotherapy market is forecast to hit $115 billion by 2023. Overall strong growth rates are expected due to a significant unmet need and increasing trends of hematological cancers.
This report covers:
An overview of cancer immunotherapy that includes: monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
Focus on current trends in cancer immunotherapies that include: anti-PD-1 and anti-PDL1 drugs, Dendritic cell vaccines, T-cell therapies, and cancer vaccines.
Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
Descriptions of more than 23 cancer immunotherapeutics approved and used as targeted drugs
Insight into the various immunotherapeutics available for specific cancer types.
Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
Overall global cancer therapeutics market, leading market players and the best selling cancer drugs.
Detailed account of the market for cancer immunotherapeutics by geography, indication, company, and individual drugs.
Profiles, marketed products, and products in the pipeline of 79 companies that are located globally
A summary table to identify the category of immunotherapy drugs offered by the 79 companies.
A specific chapter on the CAR-T industry detailing manufacturing, regulations, and pricing
Key Topics Covered:
1.0 Executive Summary
2.0 Cancer Immunotherapy: An Overview
3.0 Current Status of Cancer Immunotherapy: An Overview
4.0 Challenges in Cancer Medicine Research: An Overview
5.0 Cancer Immunotherapeutic Products: An Overview
6.0 Available Immunotherapies for Cancer by Disease Type: An Overview
7.0 Cancer Incidence and Mortality: An Overview
8.0 Global Oncology Market Analysis and Forecast to 2023
9.0 Market for Cancer Immunotherapy
10.0 Company Profiles
11.0 Cancer Immunotherapy Market Participants by Product Segment
12.0 CAR T Therapy
13.0 Regulations Pertaining to Immunotherapy Regulation in the USA
14.0 Regulations for Immunotherapy in Japan
15.0 European Regulation and Immunotherapeutics
16.0 Manufacturing of Immunotherapies
17.0 Supply Chain & Logistics
18.0 Pricing & Cost Analysis
19.0 Current Deals Within the CAR T Market
20.0 CAR T Therapy Company Case Studies
Aduro BioTech Inc
Antigen Express Inc
Activartis Biotech GmbH
Argos Therapeutics Inc
Bavarian Nordic A/S
Bellicum Pharmaceuticals Inc
Biogen Idec Inc
Bristol-Myers Squibb Company
DenDrit Biotech USA
EMD Serono Inc
Eli Lilly and Co.
Galena Biopharma Inc
Heat Biologics Inc
Immatics Biotechnologies GmbH
ImmunoCellular Therapeutics Ltd.
Inovio Pharmaceuticals Inc
Janssen Biotech Inc
Juno Therapeutics Inc
Kite Pharma Inc
MabVax Therapeutics Holdings Inc
Merck & Co., Inc
Merrimack Pharmaceuticals Inc
NewLink Genetics Corp.
Northwest Biotherapeutics Inc
OSE Pharma SA
Oxford BioTherapeutics Ltd.
Prima BioMed Ltd.
Progenics Pharmaceuticals Inc
Regen Biopharma Inc
Roche Holdings Inc
Seattle Genetics Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Synthon Pharmaceuticals Inc
TVAX Biomedical Inc
Viventia Biotechnologies Inc
Ziopharm Oncology Inc
For more information about this report visit https://www.researchandmarkets.com/r/ev41gi
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005358/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900